1. Terapi injeksi hormon testosteron dosis rendah dan dosisi tinggi dapat meningkatkan kadar testosteron dalam plasma darah dan berperan dalam peningkatan kadar β amyloid pada cairan serebrospinal
2. Hormon testosteron berperan dalam menurunkan tingkat kematian sel dan akumulasi plak β amyloid pada jaringan otak
3. Marmut tua sebagai hewan model untuk terapi hormon dalam mempelajari pembentukan plak β amyloid yang berhubungan dengan salah satu patogenesis penyakit Alzheimer.
Saran
Penelitian ini belum mempelajari peran testosteron dalam memperbaiki fungsi kognitif, memori yang berkaitan dengan patogenesis penyakit Alzheimer. Diharapkan dalam penelitian lebih lanjut dilakukan pengamatan terhadap parameter tersebut sehingga dapat mendukung peran terapi testosteron dalam memperbaiki kondisi manusia yang menderita penyakit Alzheimer.
DAFTAR PUSTAKA
Ahlbom E, Prins GS, Ceccatelli S. 2001. Testosteron protects cerebellar granule cells from oxidative stress induced cell death through a receptor mediated mechanism. Brain Res 892:255–262.
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL. 2000. Inflammation and Alzheimer's disease. Neurobiology of Aging 21:383–421.
Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, Hines M. 1998. Androgenbehavior correlations in hypogonadal men and eugonadal men. II.Cognitive abilities. Horm Behav 33:85–94.
Almeida OP, Flicker L. 2003. Testosteron and dementia: too much ado about too little data. J Br Menopause Soc 9:107–110
Anderson M and Froimovitch. 1974. Simplified method of guinea pig castration. Can. Vet. J. : 15(4): 126-127
Azcoitia I, Sierra A, Veiga S, Honda S, Harada N, Garcia-Segura LM. 2001. Brain aromatase is neuroprotective. J Neurobiol 47(4): 318-29
Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. 1999. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 107:123–136.
Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. 1999. The Journal of Clinical Endocrinology and Metabolism 84:3681–3685.
Barron AM, Verdile G, Martins RN. 2006. The role of gonadotropins in Alzheimer's disease: potential neurodegenerative mechanisms. Endocrine 29:257–269.
Bentahir M, Nyabi O, Verhamme J. 2006. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem
96(3):732–742.
Beck M, Bigl V, Robner S. 2003. Guinea pigs as a transgenic model for APP porcessing in vitro and in vivo. Neurochem Res 28: 647-654
Beck M, Brugner MK, Holzer M, Stahl T and Bigl V. 1998. The use of guinea pigs (Cavia sp.) as a model to study porcessing of the amyloid precursor protein (APP). Euro J Neurosci (Suppl.10): Abstract 92
Bhasin S, Storer TW, Berman N, et al. 1997. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 82:407-413.
Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M et al. 2003. Time sequence of maturation of dystrophic neuritis associated with Aβ deposits in APP/PS1 transgenic mice. Exp Neurol. 184:247-26
Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS. 2004. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid- beta deposition. J Biol Chem 279:20539–20545.
Braak H, Braak E.1997. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18(4):351–357.
Braak H, Braak E. 1990. Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 49:215–224
Brickell KL, Steinbart EJ, Rumbaugh M. 2006. Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease. Arch Neurol 63(9):1307–1311.
Brooks BP, Merry DE, Paulson HL, Lieberman AP, Kolson DL, Fischbeck KH. 1998. A cell culture model for androgen effects in motor neurons. J Neurochem 70(3): 1054-60
Burger H, de Laet CE, van Daele PL, Weel AE, Witteman JC, Hofman A, Pols HA. 1998. Risk factors for increased bone loss in an elderly population: the Rotterdam Study. Am J Epidemiol 147:871– 879.
Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JAR, Perry VH, Weller RO. 2008. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries. Significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 34:131-144.
Caroll JC and Rosario ER. 2012. The potential use of hormone-based therapeutics for the treatment of Alzheimer’s disease. Current Alzheimer research (9): 18-34
Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, Smith MA. 2006. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta 1762:447–452.
Checler F. 1995. Processing of the beta-amyloid precursor protein and its
regulation in Alzheimer’s disease. J Neurochem 65: 1431-1444
Cooke BM. 2006. Steroid-dependent plasticity in the medial amygdala. Neuroscience 138: 997–1005.
Daniel PP. 2010. Neuropathology of Alzheimer’s Disease. Mt Sinai J med 77:32- 42
Day JR, Frank AT, O'Callaghan JP, Jones BC, Anderson JE. 1998. The effect of age and testosteron on the expression of glial fibrillary acidic protein in the rat cerebellum. Exp Neurol 151:343–346.
Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 alpha- dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol. 1992;88:15-22.
Dodson R and Gorski R A. 1993. Testosterone propionate administration prevents the loss of neurons within the central part of the medial preoptic nucleus. J. Neurobiol. 24:80-88.
Dong Y, Benveniste EN . 2001. Immune function of astrocytes. Glia 36: 180-190 Du P, Wood KM, Rosner MH, Cunningham D, Tate B and Geoghegan KF. 2007.
Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry. J Pharmacol Exp Ther 320: 1144-1452
Dubal D, Shughrue P, Wilson M, Merchenthaler I and Wise P. 1999. Estradiol modulates Bcl-2 in cerebral ischemia: a potential role for estrogen receptors. J. Neurosci. 19: 6385-6393.
Dunn JF, Nisula BC, Rodbard D. 1981. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid- binding globulin in human plasma. J Clin Endocrinol Metab. 53:58-68.
Eckman EA, Reed DK, Eckman CB. 2001. Degradation of the Alzheimer’s amyloid beta peptide by endothelinconverting enzyme. J Biol Chem 276:24540–24548.
Edinger KL, Frye CA. 2005. Testosteron's anti-anxiety and analgesic effects may be due in part to actions of its 5alpha-reduced metabolites in the hippocampus. Psychoneuroendocrinology 30:418–430.
Eng LF, Ghirnikar RS. 1994. GFAP and astrogliosis. Brain Pathol 4:229-237 Eng LF,Yu AC, Lee YL. 1992. Astrocytic response to injury. Prog Brain Res
94:353-365
Esiri MM and Morris JH. 2004. Practical Approach to Pathological Diagnosis in the Neuropathology of Dementia. Second edition. Cambridge University Press. 53-55
Esiri MM, Wilcock GK. 1986. Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiat 49:1221-1226.
Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. 2002. Age trends in the level of serum testosteron and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87:589– 598.
Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ. 2002. Testosteron administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 282:E601– E607.
Frye CA, Reed TA. 1998. Androgenic neurosteroids: anti-seizure effects in an animal model of epilepsy. Psychoneuroendocrinology 23:385–399. Frye CA, Seliga AM. 2001. Testosteron increases analgesia, anxiolysis, and
cognitive performance of male rats. Cogn Affect Behav Neurosci 1:371– 381.
Gandy S, Almeida Op, Fonte J, Lim D, Waterrus A, Spry N. 2001. Chemical
andropouse and amyloid β-peptide. JAMA 285:2195-2196
Ghersi EP, Gorevic D, Ohiso J, Frangione B, Patlak S, Fenstermacher JD. 1996. Fate of cerebrospinal fluid-borne amyloid-beta peptide: rapid clearence into blood and appreciable accumulation by cerebral arteries. J Neurochem 67: 880-883
Gillett MJ, Martins RN, Clarnette RM, Chubb SA, Bruce DG, Yeap BB. 2003. Relationship between testosteron, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J Alzheimers Dis 5:267–269.
Goodenough S, Engert S, Behl C. 2000. Testosteron stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via activation of the mitogen-activated protein kinase pathway. Neurosc. Lett 96: 49-52
androgen supplementation. J Steroid Biochem Mol Biol 85:349–355. Gouchie C, Kimura D. 1991. The relationship between testosteron levels and
cognitive ability patterns. Psychoneuroendocrinology 16:323–334. Gouras GK, Xu H, Gross RS, Greenfield JP, Hai B, Wang R, Greengard P. 2000.
Testosteron reduces neuronal secretion of Alzheimer's beta-amyloid peptides. PNAS 97:1202–1205
Gray A, Feldman H, McKinlay J, Longcope C. 1991. Age disease and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73:1016–1025.
Griffin WST, Sheng JG, Mark RE, in: Wasco, W., R.E.Tanzi (Eds). 1997. Molecular Mechanisms of Dementia. Human Press, Totowa NJ, USA. 169-176
Haass C, Selkoe DJ. 2 0 0 7 . Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-12.
Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. 1992. Targeting of cell- surface beta-amyloidprecursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357(6378):500–503 Hammond J, Le Q, Goodyer C, Gelfand M, Trifiro M, LeBlanc A. 2001.
Testosteron-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem 77:1319–1326.
Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353–356 Hardy JA, Higgins GA. 1992. Alzheimer' disease: the amyloid cascade
hypothesis. Science 256:184–185.
Haren MT, Wittert GA, Chapman IM, Coates P, Morley JE. 2005. Effect of oral testosteron undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas 50:124– 133.
Heinlein CA, Chang C. 2002. The roles of androgen receptors and androgen- binding proteins in nongenomic androgen actions. Mol Endocrinol. 16:2181-2187.
Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. 2007. How common are the “common” neurologic disorders? Neurology 68:326-337.
Hogervorst E, Lehmann DJ, Warden DR, McBroom J, Smith AD. 2002. Apolipoprotein E epsilon4 and testosteron interact in the risk of Alzheimer's disease in men. Int J Ger Psych 17:938–940.
Hone E, Martins IJ, Fonte , Martins RN. 2003. Apolipoprotein E influences amyloid-beta clearence from the murine periphery. J Alzheimer’s Dis 5:1-8 Hoozemans J J , Veerhuis R, Van Haastert ES, 2005. The unfolded protein re- sponse is activated in Alzheimer’s disease. Acta Neuropathol 110:165- 72.Harman SM, Tsitouras PD. 1980. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clinic EndocrinolMetab, 51:35–40.
Hubbard BM, and Handerson JM. 1981. Age, senile dementia and ventricular enlargement. J Neurol neurosurg Psychiatry 44:631- 635
Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al.2000. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6(2): 143-50
Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. 2001. Metabolic regulation of brain Aβ by neprilysin. Science 292:1550–1552.
Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. 2002. Region-specific reduction of Abeta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 70:493–500.
Iwata N, Higuchi M, Saido TC. 2005. Metabolism of amyloid-beta peptide and
Alzheimer’s disease. Pharmacol Ther 108:129–48.
Iwatsuko T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. 1994. Visualization of A beta 42(43) and A beta 40 in senile plaques with end- specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13(1):45–53.
Joachim CL, Morris JH, Selkoe DJ. 1988. Clinically diagnosed Alzheimer’s disease:autopsy result in 150 cases. Ann Neurol 24:50-56
Jones RD, Pugh PJ, Hall J, Channer KS, Jones TH. 2003. Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse. Eur J Endocrinol 148:111– 120.
Jones KJ, Brown TJ, Damaser M. 2001. Neuroprotective effects of gonadal steroids on regenerating peripheral motoneurons. Brain Res Rev 37:372– 382.
Kaufman JM, Vermeulen A. 2005. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833-876 Kerr JE, Allore RJ, Beck SG, Handa RJ. 1995. Distribution and hormonal
regulation of androgen receptor (AR) and AR messenger ribonucleic acid in the rat hippocampus. Endocrinology 136:3213–3221.
Kettemann H, Hanisch UK, Noda M, Verkhratsky A. 2011. Physiology of Microglia. Physiol Rev 91:461-553
Kovacs EG, MacLusky NJ, Leranth C. 2003. Effects of testosteron on hippocampal CA1 spine synaptic density in the male rat are inhibited by fimbria/fornix transection. Neuroscience 122:807–810.
Kujawa KA, Emeric E, Jones KJ. 1991. Testosteron differentially regulates the regenerative properties of injured hamster facial motoneurons. J Neurosci 11:3898–3906.
Kumar V, Abbas AK, Fausto N. 2005. Robbins and Cotran Pathologic Basic of Diseases. 7th edition. Elsevier Saunders
LaFerla FM, Oddo S. 2005. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 11:170–176.
Leissring MA, Farris W, Chang AY, 2003. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and pre- mature death. Neuron 40:1087-93.
Leranth C, Petnehazy O, MacLusky NJ. 2003. Gonadal hormones affect spine synaptic density in the CA1 hippocampal subfield of male rats. J.Neurosci 23:1588–1592.
Leranth C, Prange-Kiel J, Frick KM, Horvath TL. 2004. Low CA1 spine synapse density is further reduced by castration in male non-human primates. Cereb Cortex 14:503–510.
Levin-Allerhand J, McEwen BS, Lominska CE, Lubahn DB, Korach KS. and Smith J D. 2001. Brain regionspecific up-regulation of mouse apolipoprotein E by pharmacological estrogen treatments. J. Neurochem. 79,796–803.
Love S, Miners S, Palmer J, Chalmers K, Kehoe P. 2009. Insights intthe pathogenesis and pathogenicity of cerebral amyloid angiopathy. Front Biosci 14:4778-4792
Lund TD, Hinds LR, Handa RJ. 2006. The androgen 5alpha-dihydrotestosteron and its metabolite 5alphaandrostan- 3beta, 17beta-diol inhibit the hypothalamo-pituitary-adrenal response to stress by acting through estrogen receptor beta-expressing neurons in the hypothalamus. J Neurosci 26:1448– 1456.
Lu S, Simon NG, Wang Y, Hu S.1999. Neural androgen receptor regulation:effects of androgen and antoandrogen. J Neurobiol 41: 501- 505
Matsumoto AM. 2002. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci, 57:M76–99.
McAllister C, Long J, Bowers A, Walker A, Cao P, Honda S, et al. 2010. Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment. J Neurosci 30(21): 7326-34
McPhaul M, Young M. 2001. Complexities of androgen action. J Am Acad Dermatol 45: S87–S94.
Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. 2006. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 65:1012-1021.
Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. 2004. Free testosteron and risk for Alzheimer disease in olderly men. Neurol 62:188-193
Morley JE.2001. Androgens and aging. Maturitas 38:61–71.
Morley JE, Perry HM. 2003. Androgen terapi of male hypogonadism in older males. The Journal of Steroid Biochemistry and Molecular Biology 85:367–373.
Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT. 2003. Endogenous sex hormones in men aged 40–80 years. Eur J Endocrinol 149:583–589
Neaves WB, Johnson L, Porter JC, et al. 1984. Leydig cell number, daily sperm production, and serum gonadotropin levels in aging men. J Clinical Endocrinol Metab, 59:756–63.
protect against apoptosis in hippocampal neurones. J Neuroendocrinol 22(9): 1013-22
Nguyen TV, Yao M, Pike CJ. 2005. Androgens activate mitogen activated protein kinase signaling: role in neuroprotection. J Neurochem 94:1639–1651.
Nussbaum RL, Ellis CE. 2003. Alzheimer’s disease and Parkinson’s disease. N
Engl J Med 348(14):1356–1364.
Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. 2003. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24:1063–1070.
Page ST, Amory JK, Bowman FD, et al. 2005. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 90:1502–10.
Pappasazomenos S. 1997. The heat shock induced hyperphosphorylation of tau is estrogen independent and prevented by androgens: implications for Alzheimer disease. Proc Natl Acad Sci USA 94: 6612-6617
Pike CJ. 2001. Testosterone attenuates beta-amyloid toxicity in cultured hippocampal neurons. Brain Res 919(1): 160-5
Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, SelkoeDJ. 1998. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273:32730–32738.
Querfurth HW and LaFerla FM. 2010. Mechanisme of Alzheimer’s Disease. N Engl J Med 362: 329-344
Ramsden M, Nyborg A, Murphy M, Chang L, Stanczyk F, Golde T, Pike CJ. 2003. Androgens modulate b amyloid level in rat brain. J Neurochem 87:1052-1055
Ramsden M, Shin TM, Pike CJ. 2003. Androgens modulate neuronal vulnerability to kainate lesion. Neuroscience 122(3): 573-8
Richmond EJ, Rogol AD. 2007. Male pubertal development and the role of androgen therapy. Nat ClinPract Endocrinol Metab. 3:338-344.
Rosario ER, Chang, L., Head, E.H., Stanczyk, F. Z., Pike, C. J. 2009. Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer’s disease Neurobiol Aging [Epub ahead of print]
Rosario ER, Carroll J, Pike CJ. 2010. Testosterone regulation of Alzheimer- like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways. Brain Res 1359: 281-90
Rehman HU, Masson EA. 2001. Neuroendocrinology og aging. Age Ageing 30:279-287
Rosario ER, Carroll JC, Oddo S, LaFerla FM, Pike JC. 2006. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci 26:13384–13389
Rosario ER and Pike CJ. 2008. Androgen regulation of β-amyloid protein and the
risk of Alzheimer’s disease. Brain Res. Rev. 57(2): 444-453
Salim ES, Hongzhu, Jin Yu, Gage FH, Verma IM, Kindy MS. 2007. Neprilysin
protects neurons against Aβ peptide toxicity. Brain Res 4:1152:191-200
Sarasa M and Pesini P. 2009. Natural non transgenic animals model for research
Schubert M, Jockenhovel F. 2005. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects. J Endocrinol Invest. 28:23-27.
Sherwood L. 2001. Fisiologi Manusia dari Sel ke Sistem. Brahm U. Pendit, penerjemah; Beatricia I. Santoso, editor. Jakarta. EGC. Terjemahan dari : Human Physiology: from cells to system
Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, Iwatsubo T, Saido TC. 2001. Neprilysin degrades both amyloid beta peptides 1-40 and 1-42most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 276:21895–901.
Shoji M, Golde T, Ghiso J. 1995. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258(5078):126–129. Shores MM, Moceri VM, Sloan KL, et al. 2005. Low testosterone levels predict
incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry, 66:7–14.
Silverbeg GD, Mayo M, Saul T, Rubenstein E, McGuire D. 2003. Alzheimer’s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology; a hypotesis. Lancet Neurol 2: 506-511
Simerly RB, Chang C, Muramatsu M, Swanson LW. 1990. Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: an in situ hybridization study. J Comp Neurol 294(1): 76-95
Srikanthan P, Karlamangla AS. 2011. Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third national health and nutrition examination survey. J Clin Endocrinol Metab 96:2898–903
Strittmatter WJ, Roses AD. 1995. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A 92:4725–4727.
Sternbach H. 1998. Age-associated testosterone decline in men: clinical issues for psychiatry. Am. J. Psychiatry 155: 1310-1318.
Swerdloff RS, Wang C. 1993. Androgen deficiency and aging in men. West J Med 159:579–585.
Tangredi JF, Buxton LL. 2001. Hypertension as a complication of topicaltestosterone therapy. Ann Pharmacother. 35:1205–1207.
Tirassa P, Thiblin I, Agren G, Vigneti E, Aloe L and Stenfors C. 1997. High-dose anabolic steroids modulate concentration of nerve growth factor and expression of its low afinity receptor (p75-NGFr) in male rat brain. J. Neurosci. Res. 47:198-207.
Tohgi H, Utsugisawa K, Yamagata M, Yoshimura M. 1995. Effects of age on messenger RNA expression of glucocorticoid, thyroid hormone, androgen, and estrogen receptors in postmortem human hippocampus. Brain Res 700:245–253.
Traish AM, Abdou R, Kypreos KE. 2009. Androgen deficiency and atherosclerosis: The lipid link. Vascul Pharmacol. 51:303–13.
Turner PR, O'Connor K, Tate WP, Abraham WC. 2003. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70:1–32.
Measures of bioavailable serum testosteron and estradiol and their relationship with muscle strength, bone density, and body composition in elderly men. J. Clin. Endocrinol. Metab. 85:3276-3282
von Eckardstein S, Nieschlag E. 2002. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl. 23:419–425.
Wahjoepramono EJ, Wijaya LK, Taddei K, Martins G, Howard M, Ruyck Kd, Bates K, Dhaliwald SS, Verdile G, Carruthers M, Martins RN. 2008. Distinct Effects of Testosteron on Plasma and Cerebrospinal Fluid Amyloid-b Levels. J Alzheimer's D 15(1): 129–137.
Wahjoepramono EJ. 2009. Efek kastrasi dan suplementasi testosteron pada metabolisme beta amyloid di cairan serebrospinal pada marmut. Disertasi Program Pascasarjana Universitas Hasanuddin, makasar
Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. 2008. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol 18:253-266.
Wilbert DM, Griffin JE, Wilson JD. 1983Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab 56:113- 120. Winters SJ, Clark BJ. 2003. Testosterone synthesis, transport transport and
metabolism. In: Winters SJ, Clark BJ, eds. Androgens in Health and Disease : 3-22.
Wilson JD. 1988. Androgen abuse by athletes. Endocr Rev. 9:181–199.
Wilson EM. 2007. Muscle-bound? A tissue-selective nonsteroidal androgen receptor modulator. Endocrinology 148:1–3.
Woolley CS, Weiland NG, McEwen BS and Schwartzkroin PA. 1997. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J. Neurosci. 17: 1848-1859.